Their next big stock grant is when they get their first EUA or approval according to NP so he isn’t going anywhere, nor will there be a buyout until they get that next chunk . Those shares usually are on an accelerating vesting schedule should they get acquired. Mahoob is a great addition but definitely a “lab” guy who hopefully, will stay focused on all the mechanics of fda approvals. Kelly should be the face for any timelines associated with drug approvals , etc